欧洲疾控中心：传染病威胁报告（2025年5月3日-5月9日，第19周）（英文版）

In a news item published on 7 May 2025, the European Medicines Agency (EMA) informed of 17 serious adverse events (SAEs) that had been reported worldwide in people aged between 62 and 89 years who had received the live attenuated chikungunya vaccine Ixchiq, including two cases resulting in death. This corresponds to an increase of two cases from the previous information published by EMA as of 30 April 2025. EMA also reported in a news item on 7 May 2025 that the agency’s Pharmacovigilance Ris